LICENSE AGREEMENTS AND COLLABORATIONS (Details Textual) (USD $)	3 Months Ended		9 Months Ended		18 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2012 Collaboration Agreement [Member]	Sep. 30, 2012 Collaboration Agreement [Member]	Sep. 30, 2012 LFB Biotechnologies [Member]	Dec. 31, 2011 LFB Biotechnologies [Member]
Stock Issued During Period Shares License Option									132,000
Possible milestone payments to pay upon successful achievement of certain milestones								$ 31,000,000
Bussiness Acquisiton Purchase Agreement Period Description								The license will terminate on a country by country basis upon the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated.
Sale of Stock, Number of Shares Issued in Transaction								7,368,000
Common Stock Value Subscribed Subsidiary Sale Of Stock								15,000,000
Common Stock Shares Subscribed Subsidiary Sale Of Stock								7,500,000
Noncash stock expense associated with in-licensing agreement	0	0	16,578,000	297,000	16,875,000			16,578,000
Subsidiary Shares Conversion Shares To Be Issued								7,500,000
Payments Towards License								0
Noncontrolling Interest, Description								LFB Group owns less than 10% of the outstanding Company Common Stock.
Milestone Payment						1,000,000	1,000,000
Potential Royalty Payment	$ 250,000,000		$ 250,000,000		$ 250,000,000